What happened with ADRX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
ADARx Pharmaceuticals develops drugs designed to reduce disease-related proteins by silencing the RNA instructions cells use to make them, an approach called small interfering RNA, or siRNA. Its proprietary technologies help design these molecules and deliver them to selected cells. Its wholly owned clinical programs include agazisiran for complement-mediated diseases, onvuzosiran for hereditary angioedema and ADX-626 for thrombotic diseases. Earlier-stage programs aim to reach fat tissue for obesity and neurons for neurodegenerative diseases.
The company has no approved products or product-sales revenue. Its revenue comes from its AbbVie collaboration, where ADARx researches siRNA therapies against agreed targets in neuroscience, immunology and oncology. AbbVie paid an upfront fee and can obtain exclusive worldwide licenses for individual targets. Further option and milestone payments depend on AbbVie’s decisions and development progress; royalties depend on eventual product sales. The agreement also restricts ADARx’s independent work on covered targets.
ADARx therefore depends on AbbVie for its current revenue and on financing to support continued development. Its own drug candidates must complete development and gain regulatory approval before they can generate sales. Expanding beyond liver-directed treatments also depends on delivering siRNA effectively and selectively to other tissues. The company relies on outside manufacturers rather than operating its own production facilities.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
ADARx’s reported revenue depends on AbbVie, which pays for research into gene-silencing medicines and the option to license them for development and sale. Watch AbbVie’s decisions to select targets and exercise those options: the May 2025 agreement brought ADARx $335 million upfront, with further payments contingent on options and milestones.
Ionis already sells DAWNZERA to prevent hereditary angioedema attacks, the same use ADARx is pursuing with onvuzosiran. DAWNZERA’s U.S. sales are the concrete line to watch against ADARx’s planned injections every three or six months.
Arrowhead competes with ADARx in kidney disease and obesity, with both developing medicines that silence genes through RNA interference. Its kidney-disease and obesity trial results are the relevant comparison for ADARx’s agazisiran and fat-tissue-targeted ADX-077, rather than sales of Arrowhead’s triglyceride treatment REDEMPLO.
Alnylam competes with ADARx in obesity and neurodegeneration using gene-silencing siRNA medicines, and their technologies for getting RNA into tissues overlap. Watch Alnylam’s progress in those diseases and RNA delivery alongside ADARx’s fat-tissue-targeted ADX-077 and neuron-targeted ADX-199.
Intellia’s Phase 3 lonvo-z competes for the hereditary angioedema prevention market ADARx seeks with onvuzosiran, using gene editing rather than RNA silencing. Watch lonvo-z’s development and approval progress: Intellia planned a U.S. launch in the first half of 2027, subject to both.
BioCryst already earns revenue from once-daily oral ORLADEYO, competing with ADARx’s planned injectable onvuzosiran to prevent hereditary angioedema attacks through the kallikrein pathway. ORLADEYO sales give a concrete view of the oral-treatment market against which ADARx’s three- or six-month injections would compete.
Pharvaris is developing oral deucrictibant to prevent hereditary angioedema attacks, competing with ADARx’s long-acting injectable onvuzosiran. Watch the Phase 3 prevention study of its extended-release tablet; the positive Phase 3 results reported in 2025 were for on-demand treatment, not prevention.
Vera’s atacicept competes with ADARx’s agazisiran for IgA nephropathy, acting on different parts of the immune system. Watch atacicept’s U.S. approval review for adults with the disease: Vera filed in November 2025 after its Phase 3 trial met the primary endpoint at week 36.
Novartis, which sells prescription medicines, competes with ADARx’s agazisiran in kidney diseases and paroxysmal nocturnal hemoglobinuria, and with its blood-clotting-disease program. Its news in those disease areas is the relevant comparison for agazisiran and ADX-626, which ADARx is developing for secondary stroke prevention.
Takeda is an established seller of hereditary angioedema preventive treatments, competing for the patients ADARx hopes to reach with onvuzosiran. Watch its HAE prevention business rather than its top-selling bowel-disease medicine ENTYVIO when assessing ADARx’s planned three- or six-month injections.
AstraZeneca competes with ADARx in paroxysmal nocturnal hemoglobinuria, one of the complement-mediated diseases ADARx is targeting with agazisiran. Its developments in that patient group are more relevant to agazisiran than sales of its cancer medicines.
Silence and ADARx both develop liver-targeted gene-silencing siRNA medicines and receive payments from pharmaceutical research partners, exposing them to similar clinical and licensing decisions. Watch partner continuation decisions: AstraZeneca notified Silence on March 4, 2026 that it would not develop SLN312 beyond Phase 1.
Wave competes with ADARx in RNA medicines for obesity and in technologies for delivering RNA to liver and non-liver tissues. Watch Wave’s obesity progress and delivery results against ADARx’s fat-tissue-targeted ADX-077; Wave’s pharmaceutical partner has also selected four programs spanning liver and non-liver tissues to advance toward development candidates.
Annexon’s vonaprument competes with ADARx’s agazisiran to treat geographic atrophy, but targets the classical complement pathway rather than the alternative pathway. Watch vonaprument’s clinical results as a comparison between those approaches; Annexon had no product-sale revenue through December 31, 2025.
Novartis AG earningsNVS
Novartis’s report will show how its kidney-disease, PNH and clotting-disease businesses compete with ADARx’s related drug candidates.
Read Novartis’s kidney-disease and PNH business separately from its clotting-disease business. Strength in those areas would show established medicines competing strongly for patients and market share, raising the bar for ADARx’s agazisiran and ADX-626; weakness would point to less pressure, not prove ADARx’s candidates will work.
Fed Interest Rate Decision
For ADARx, the Fed’s interest-rate decision matters because it can change the interest income the company earns as its Treasury securities and other short-term investments mature and are reinvested.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can lift the yield on reinvested holdings, increasing ADARx’s interest income; the change may flow through gradually as investments mature.
If it comes in below expectations
Lower rates can reduce the yield as holdings are reinvested, decreasing ADARx’s interest income and leaving less other income to offset its operating expenses.
Alnylam Pharmaceuticals, Inc. earningsALNY
Alnylam’s report will show how its obesity and neurodegeneration programs and RNA delivery progress compare with ADARx’s efforts to reach fat and nerve cells.
Read Alnylam’s obesity and neurodegeneration progress alongside what it reports about RNA delivery. Advancing programs and evidence of delivery would strengthen the case that gene-silencing medicines can reach tissues beyond the liver, a relevant benchmark for ADARx’s fat-targeted ADX-077 and neuron-targeted ADX-199; setbacks or delivery limits would leave that hurdle unresolved.
Takeda Pharmaceutical Company Limited earningsTAK
Takeda’s report will show whether its hereditary angioedema prevention business is holding patients, a measure of the market ADARx’s onvuzosiran would enter.
Focus on Takeda’s hereditary angioedema (HAE) prevention business, not its bowel-disease medicines. A strong business would suggest existing treatments retain patients, so ADARx’s planned long-acting injection onvuzosiran would need to win them over; weakness could mean less competition from established treatment, but would not show patients will switch to ADARx.
ABBVIE INC. earningsABBV
Any disclosed target selections or license-option exercises in AbbVie’s report would show whether conditions for further payments under its ADARx collaboration are being met.
Look for disclosed selections of ADARx collaboration targets or exercises of license options. Such activity would show the collaboration moving toward potential option or milestone payments; if none is disclosed, further payments remain conditional and unconfirmed, and silence alone does not mean the agreement has ended.
Vera Therapeutics, Inc. earningsVERA
Vera Therapeutics’ report will show whether its IgA nephropathy drug atacicept is advancing toward approval, a competing path for ADARx’s agazisiran.
Watch whether atacicept’s IgA nephropathy review advances and whether Vera reports new clinical or regulatory information. Continued progress would bring another potential treatment closer to patients and sharpen competition for ADARx’s agazisiran; delays or adverse information would weaken that competing path, not prove agazisiran works.
